Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers

Frontiers in Pharmacology

Volumn 3 JAN, Issue , 2012, Pages

  Matsunaga, Toshiyuki ^a   Wada, Yasuhiro ^a   Endo, Satoshi ^a   Soda, Midori ^b   El Kabbani, Ossama ^c   Hara, Akira ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Aldo keto Reductase 1B10; Chemotherapy; Proliferation; Resistance

Indexed keywords

2 (4 METHOXYPHENYLIMINO) 7 HYDROXY N (PYRIDINE 2 YL) 2H CHROMENE 3 CARBOXAMIDE; 4 HYDROXYACETOPHENONE; ALDEHYDE REDUCTASE; ALDEHYDE REDUCTASE INHIBITOR; ALDO KETO REDUCTASE 1B10; ALDO KETO REDUCTASE 1C; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARBOXYLIC ACID; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DAUNORUBICINOL; DIDEMETHOXYCURCUMIN; DOXORUBICIN; ENZYME INHIBITOR; EPIRUBICIN; FARNESOL; IDARUBICIN; IDARUBICINOL; LITHOCHOLIC ACID; MITOMYCIN; OLEANOLIC ACID; OXALIPLATIN; RETINOIC ACID; TOLRESTAT; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME METABOLISM; HUMAN; IC 50; LIVER; LIVER TUMOR; LOW DRUG DOSE; LUNG; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT TRANSFORMATION; MEDULLOBLASTOMA; METASTASIS; MOLECULAR MECHANICS; MORPHOGENESIS; NEOPLASM; OVARY CANCER; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PRENYLATION; REGULATORY MECHANISM; SKIN CANCER; SOLID TUMOR; STOMACH CANCER; UPREGULATION; UTERINE CERVIX CANCER;

EID: 84865998331     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00005     Document Type: Article

References (107)

1. Agyeman, A. S., Chaerkady, R., Shaw, P. G., Davidson, N. E., Visvanathan, K., Pandey, A., and Kensler, T. W. (2012). Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphanetreated human breast epithelial cells reveals common expression profiles. Breast Cancer Res. Treat. PMID: 21597922. [Epub ahead of print].
2. Alexandre, J., Hu, Y., Lu, W., Pelicano, H., and Huang, P. (2007). Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res. 67, 3512-3517.
3. Almond, J. B., and Cohen, G. M. (2002). The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433-443.
4. Ax, W., Soldan, M., Koch, L., and Maser, E. (2000). Development of daunoru- bicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 59, 293-300.
5. Baba, S. P., Barski, O. A., Ahmed, Y., O'Toole, T. E., Conklin, D. J., Bhatnagar, A., and Srivastava, S. (2009). Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue. Diabetes 58, 2486-2497.
6. Bacolod,M. D.,Lin,S. M.,Johnson,S. P., Bullock, N. S., Colvin, M., Bigner, D. D., and Friedman, H. S. (2008). The gene expression profiles of medulloblastoma cell lines resistant to Matsunaga et al. AKR1B10 and drug-resistant cancers preactivated cyclophosphamide. Curr. Cancer Drug Targets 8, 172-179.
7. Bains, O. S., Grigliatti, T. A., Reid, R. E., and Riggs, K. W. (2010). Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J. Pharmacol. Exp. Ther. 335, 533-545.
8. Balendiran, G. K. (2009). Fibrates in the chemical action of daunorubicin. Curr. Cancer Drug Targets 9, 366-369.
9. Balendiran, G. K., Martin, H. J., El- Hawari, Y., and Maser, E. (2009). Cancer biomarker AKR1B10 and carbonyl metabolism. Chem. Biol. Interact. 178, 134-137.
10. Barski, O. A., Tipparaju, S. M., and Bhatnagar, A. (2008). The aldoketo reductase superfamily and its role in drug metabolism and detoxification. Drug Metab. Rev. 40, 553-624.
11. Breton, J., Gage, M. C., Hay, A. W., Keen, J. N., Wild, C. P., Donnellan, C., Findlay, J. B., and Hardie, L. J. (2008). Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma. J. Proteome Res. 7, 1953-1962.
12. Bushue, N., and Wan, Y. J. (2010). Retinoid pathway and cancer therapeutics. Adv. Drug Deliv. Rev. 62, 1285-1298.
13. Cao, D., Fan, S. T., and Chung, S. S. (1998). Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 273, 11429-11435.
14. Chen, J., Adikari, M., Pallai, R., Parekh, H. K., and Simpkins, H. (2008). Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 61, 979-987.
15. Chen, Y. J., Yuan, C. C., Chow, K. C., Wang, P. H., Lai, C. R., Yen, M. S., and Wang, L. S. (2005). Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol. Oncol. 97, 110-117.
16. Cho, J. M., Manandhar, S., Lee, H. R., Park, H. M., and Kwak, M. K. (2008). Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 260, 96-108.
17. Chow, K. C., Lu, M. P., and Wu, M. T. (2006). Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma. J. Dermatol. Sci. 41, 205-212.
18. Cory, A. H., and Cory, J. G. (2002). Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFκB activation, on drug-resistant mouse leukemia L1210 cells. Anticancer Res. 22, 3805-3809.
19. Crosas, B., Hyndman, D. J., Gallego, O., Martras, S., Parés, X., Flynn, T. G., and Farrés, J. (2003). Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem. J. 373, 973-979.
20. De Angelis, P. M., Svendsrud, D. H., Kravik, K. L., and Stokke, T. (2006). Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol. Cancer 5, 20.
21. De Vries, H. E., Witte, M., Hondius, D., Rozemuller, A. J., Drukarch, B., Hoozemans, J., and van Horssen, J. (2008). Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radic. Biol. Med. 45, 1375-1383.
22. Deng, H. B., Adikari, M., Parekh, H. K., and Simpkins, H. (2004). Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germcell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydroge- nase. Cancer Chemother. Pharmacol. 54, 301-307.
23. Deng, H. B., Parekh, H. K., Chow, K. C., and Simpkins, H. (2002). Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J. Biol. Chem. 277, 15035-15043.
24. Díez-Dacal, B., Gayarre, J., Gharbi, S., Timms, J. F., Coderch, C., Gago, F., and Pérez-Sala, D. (2011). Identification of aldoketo reduc- tase AKR1B10 as a selective target for modification and inhibition by prostaglandin A1: implications for antitumoral activity. Cancer Res. 71, 4161-4171.
25. Ebert, B., Kisiela, M., Wsól, V., and Maser, E. (2011). Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon can- cer cell lines SW-480 and HT-29. Chem. Biol. Interact. 191, 239-249.
26. Endo, S., Matsunaga, T., Kuwata, K., Zhao, H. T., El-Kabbani, O., Kitade, Y., and Hara, A. (2010a). Chromene- 3-carboxamide derivatives discov- ered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. Bioorg. Med. Chem. 18, 2485-2490.
27. Endo, S., Matsunaga, T., Soda, M., Tajima, K., Zhao, H. T., El-Kabbani, O., and Hara, A. (2010b). Selec- tive inhibition of the tumor marker AKR1B10 by antiinflammatory Nphenylanthranilic acids and glycyrrhetic acid. Biol. Pharm. Bull. 33, 886-890.
28. Endo, S., Matsunaga, T., Mamiya, H., Ohta,C.,Soda,M.,Kitade,Y.,Tajima, K., Zhao, H. T., ElKabbani, O., and Hara, A. (2009). Kinetic studies of AKR1B10, human aldose reductaselike protein: endogenous substrates and inhibition by steroids. Arch. Biochem. Biophys. 487, 1-9.
29. Endo, S., Matsunaga, T., Ohta, C., Soda, M., Kanamori, A., Kitade, Y., Ohno, S., Tajima, K., ElKabbani, O., and Hara, A. (2011). Roles of rat and human aldoketo reductases in metabolism of farnesol and geranylgeraniol. Chem. Biol. Interact. 191, 261-268.
30. Fukumoto, S.,Yamauchi, N., Moriguchi, H., Hippo, Y., Watanabe, A., Shiba- hara, J., Taniguchi, H., Ishikawa, S., Ito, H., Yamamoto, S., Iwanari, H., Hironaka, M., Ishikawa, Y., Niki, T., Sohara, Y., Kodama, T., Nishimura, M., Fukayama, M., Dosaka-Akita, H., and Aburatani, H. (2005). Overexpression of the aldoketo reductase family protein AKR1B10 is highly correlated with smokers'nonsmall cell lung carcinomas. Clin. Cancer Res. 11, 1776-1785.
31. Gallego, O., Belyaeva, O. V., Porté, S., Ruiz, F. X., Stetsenko, A. V., Shabrova, E. V., Kostereva, N. V., Far- rés, J., Parés, X., and Kedishvili, N. Y. (2006). Comparative functional analysis of human medium-chain dehydrogenases, shortchain dehydrogenases/reductases and aldoketo reductases with retinoids. Biochem. J. 399, 101-109.
32. Gallego, O., Ruiz, F. X., Ardèvol, A., Domínguez, M., Alvarez, R., de Lera, A. R., Rovira, C., Farrés, J., Fita, I., and Parés, X. (2007). Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc. Natl. Acad. Sci. U.S.A. 104, 20764-20769.
33. Grimshaw, C. E., and Mathur, E. J. (1989). Immunoquantitation of aldose reductase in human tissues. Anal. Biochem. 176, 66-71.
34. Heringlake, S., Hofdmann, M., Fiebeler, A., Manns, M. P., Schmiegel, W., and Tannapfel, A. (2010). Identification and expression analysis of the aldoketoreductase1-B10 gene in primary malignant liver tumours. J. Hepatol. 52, 220-227.
35. Higgins, C. F. (2007). Multiple mol- ecular mechanisms for multidrug resistance transporters. Nature 446, 749-757.
36. Hung, J. J., Chow, K. C., Wang, H. W., and Wang, L. S. (2006). Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarci- noma cells of lung. Anticancer Res. 26, 2949-2955.
37. Hyndman, D. J., and Flynn, T. G. (1998). Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim. Biophys. Acta 1399, 198-202.
38. Jiang, T., Chen, N., Zhao, F., Wang, X. J., Kong, B., Zheng, W., and Zhang, D. D. (2010). High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 70, 5486-5496.
39. Jin, Y., and Penning, T. M. (2007). Aldo-keto reductases and bioactivation/detoxication. Annu. Rev. Pharmacol. Toxicol. 47, 263-292.
40. Joo, J. H., and Jetten, A. M. (2010). Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett. 287, 123-135.
41. Kabututu, Z., Manin, M., Pointud, J. C., Maruyama, T., Nagata, N., Lambert, S., Lefrançois-Martinez, A. M., Martinez, A., and Urade, Y. (2009). Prostaglandin F2α synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7. J. Biochem. 145, 161-168.
42. Kang, M. W., Lee, E. S., Yoon, S. Y., Jo, J., Lee, J., Kim, H. K., Choi, Y. S., Kim, K., Shim, Y. M., Kim, J., and Kim, H. (2011). AKR1B10 is associated with smoking and smoking-related nonsmall-cell lung cancer. J. Int. Med. Res. 39, 78-85.
43. Khadir, A., Verreault, J., and Averill, D. A. (1999). Inhibition of antiox- idants and hyperthermia enhance bleomycin-induced cytotoxicity and lipid peroxidation in Chinese ham- ster ovary cells. Arch. Biochem. Bio- phys. 370, 163-175.
44. Kim, B., Lee, H. J., Choi, H. Y., Shin, Y., Nam, S., Seo, G., Son, D. S., Jo, J., Kim, J., Lee, J., Kim, J., Kim, K., and Lee, S. (2007). Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res. 67, 7431-7438.
45. Lau, A.,Villeneuve, N. F., Sun, Z., Wong, P. K., and Zhang, D. D. (2008). Dual roles of Nrf2 in cancer. Pharmacol. Res. 58, 262-270.
46. Lee, H. J., Nam, K. T., Park, H. S., Kim, M. A., Lafleur, B. J., Aburatani, H., Yang, H. K., Kim, W. H., and Goldenring, J. R. (2010). Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. Gastroenterology 139, 213-225.
47. Lee, K. W., Ko, B. C., Jiang, Z., Cao, D., and Chung, S. S. (2001). Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 12, 129-132.
48. Levonen, A. L., Landar, A., Ramachandran, A., Ceaser, E. K., Dickinson, D. A., Zanoni, G., Morrow, J. D., and Darley-Usmar, V. M. (2004). Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J. 378, 373-382.
49. Li, C. P., Goto,A.,Watanabe,A., Murata, K., Ota, S., Niki, T., Aburatani, H., and Fukayama,M. (2008). AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. Pathol. Res. Pract. 204, 295-304.
50. Li, W., Zhang, X., and Olumi, A. F. (2007). MG-132 sensitizes TRAILresistant prostate cancer cells by activating c-Fos/cJun heterodimers and repressing c-FLIP(L). Cancer Res. 67, 2247-2255.
51. Liu, J., Wen, G., and Cao, D. (2009a). Aldoketo reductase family 1 member B1 inhibitors: old drugs with new perspectives. Recent Pat. Anticancer Drug Discov. 4, 246-253.
52. Liu, Z., Zhong, L., Krishack, P. A., Robbins, S., Cao, J. X., Zhao, Y., Chung, S., and Cao, D. (2009b). Struc- ture and promoter characterization of aldo-keto reductase family 1B10 gene. Gene 437, 39-44.
53. Loeffler-Ragg, J., Mueller, D., Gamerith, G., Auer, T., Skvortsov, S., Sarg, B., Skvortsova, I., Schmitz, K. J., Mar- tin, H. J., Krugmann, J., Alakus, H., Maser, E., Menzel, J., Hilbe, W., Lindner, H., Schmid, K. W., and Zwierzina, H. (2009). Proteomic identification of aldoketo reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol. Cancer Ther. 8, 1995-2006.
54. Loignon, M., Miao, W., Hu, L., Bier, A., Bismar, T. A., Scrivens, P. J., Mann, K., Basik, M., Bouchard, A., Fiset, P. O., Batist, Z., and Batist, G. (2009). Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol. Cancer Ther. 8, 2432-2440.
55. Luo, D. X., Huang, M. C., Ma, J., Gao, Z., Liao, D. F., and Cao, D. (2011). Aldo-keto reductase family 1, member B10 is secreted through a lysosome-mediated non-classical pathway. Biochem. J. 438, 71-80.
56. Ma, J., Yan, R., Zu, X., Cheng, J. M., Rao, K., Liao, D. F., and Cao, D. (2008). Aldo-keto reductase fam- ily 1B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-α in breast cancer cells. J. Biol. Chem. 283, 3418-3423.
57. MacLeod, A. K., McMahon, M., Plummer, S. M., Higgins, L. G., Penning, T. M., Igarashi, K., and Hayes, J. D. (2009). Characterization of the cancer chemopreventive NRF2- dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 30, 1571-1580.
58. Martin, H. J., Breyer-Pfaff, U., Wsol, V., Venz, S., Block, S., and Maser, E. (2006). Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab. Dispos. 34, 464-470.
59. Martin, H. J., and Maser, E. (2009). Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem. Biol. Interact. 178, 145-150.
60. Matsunaga, T., Endo, S., Soda, M., Zhao, H. T., El-Kabbani, O., Tajima, K., and Hara, A. (2009). Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxy- curcumin: probing the active site of the enzyme with molecular mod- eling and site-directed mutagene- sis. Biochem. Biophys. Res. Commun. 389, 128-132.
61. Matsunaga, T., Shintani, S., and Hara,A. (2006). Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab. Pharmacokinet. 21, 1-18.
62. Matsunaga, T., Yamane, Y., Iida, K., Endo, S., Banno, Y., El-Kabbani, O., and Hara, A. (2011). Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms. Anticancer Drugs 22, 402-408.
63. Nagaraj, N. S., Beckers, S., Mensah, J. K., Waigel, S., Vigneswaran, N., and Zacharias, W. (2006). Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxi- col. Lett. 165, 182-194.
64. Nishinaka, T., Miura, T., Okumura, M., Nakao, F., Nakamura, H., and Terada, T. (2011). Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2. Chem. Biol. Interact. 191, 185-191.
65. Notarbartolo, M., Cervello, M., Poma, P., Dusonchet, L., Meli, M., and D'Alessandro, N. (2004). Expression of the IAPs in multidrug resistant tumor cells. Oncol. Rep. 11, 133-136.
66. O'Loughlin, C., Heenan, M., Coyle, S., and Clynes, M. (2000). Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin. Eur. J. Cancer 36, 1149-1160.
67. Park, H. W., and Beese, L. S. (1997). Protein farnesyltransferase. Curr. Opin. Struct. Biol. 7, 873-880.
68. Penning, T. M., and Lerman, C. (2008). Genomics of smoking exposure and cessation: lessons for cancer preven- tion and treatment. Cancer Prev. Res. (Phila.) 1, 80-83.
69. Pierrou,S.,Broberg,P.,O'Donnell,R.A., Pawlowski, K., Virtala, R., Lindqvist, E., Richter, A., Wilson, S. J., Angco, G., Möller, S., Bergstrand, H., Koopmann, W., Wieslander, E., Strömstedt, P. E., Holgate, S. T., Davies, D. E., Lund, J., and Djukanovic, R. (2007). Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 577-586.
70. Plebuch, M., Soldan, M., Hungerer, C., Koch, L., and Maser, E. (2007). Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett. 255, 49-56.
71. Quinn, A. M., Harvey, R. G., and Penning, T. M. (2008). Oxida- tion of PAH transdihydrodiols by human aldo-keto reductase AKR1B10. Chem. Res. Toxicol. 21, 2207-2015.
72. Roidl,A., Berger, H. J., Kumar, S., Bange, J., Knyazev, P.,and Ullrich,A. (2009). Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin. Cancer Res. 15, 2058-2066.
73. Ruiz, F. X., Gallego, O., Ardèvol, A., Moro, A., Domínguez, M., Alvarez, S., Alvarez, R., de Lera, A. R., Rovira, C., Fita, I., Parés, X., and Farrés, J. (2009). Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem. Biol. Inter- act. 178, 171-177.
74. Satow, R., Shitashige, M., Kanai, Y., Takeshita, F., Ojima, H., Jigami, T., Honda, K., Kosuge, T., Ochiya, T., Hirohashi,S.,andYamada,T. (2010). Combined functional genome sur- vey of therapeutic targets for hepato- cellular carcinoma. Clin. Cancer Res. 16, 2518-2528.
75. Schmitz, K. J., Sotiropoulos, G. C., Baba, H. A., Schmid, K. W., Müller, D., Paul, A., Auer, T., Gamerith, G., and Loeffler-Ragg, J. (2011). AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver Int. 31, 810-816.
76. Scuric, Z., Stain, S. C., Anderson, W. F., and Hwang, J. J. (1998). New mem- ber of aldose reductase family pro- teins overexpressed in human hepatocellular carcinoma. Hepatology 27, 943-950.
77. Selga, E., Noé, V., and Ciudad, C. J. (2008). Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem. Pharmacol. 75, 414-426.
78. Shen, Y., Zhong, L., Johnson, S., and Cao, D. (2011). Human aldo-keto reductases 1B1 and 1B10: a compar- ative study on their enzyme activity toward electrophilic carbonyl com- pounds. Chem. Biol. Interact. 191, 192-198.
79. Shen, Y., Zhong, L., Markwell, S., and Cao, D. (2010). Thiol-disulfide exchanges modulate aldo-keto reductase family 1 member B10 activity and sensitivity to inhibitors. Biochimie 92, 530-537.
80. Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M., and Hirohashi, S. (2008). Genetic alteration of Keap1 confers con- stitutive Nrf2 activation and resistance to chemotherapy in gallblad- der cancer. Gastroenterology 135, 1358-1368.
81. Shim, G. S., Manandhar, S., Shin, D. H., Kim, T. H., and Kwak, M. K. (2009). Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic. Biol. Med. 47, 1619-1631.
82. Sinensky, M. (2000). Recent advances in the study of prenylated proteins. Biochim. Biophys. Acta 1484,93-106.
83. Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidran- sky, D., Gabrielson, E., Brock, M. V., and Biswal, S. (2006). Dysfunctional KEAP1-NRF2 interaction in non- small-cell lung cancer. PLoS Med. 3, e420.
84. Song, D. G., Lee, J. Y., Lee, E. H., Jung, S. H., Nho, C. W., Cha, K. H., Koo, S. Y., and Pan, C. H. (2010). Inhibitory effects of polyphenols isolated from Rhus verniciflua on aldo-keto reductase family 1 B10. BMB Rep. 43, 268-272.
85. Spite, M., Baba, S. P., Ahmed, Y., Barski, O. A., Nijhawan, K., Petrash, J. M., Bhatnagar, A., and Srivastava, S. (2007). Substrate specificity and cat- alytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem. J. 405, 95-105.
86. Takemura, M., Endo, S., Matsunaga, T., Soda, M., Zhao, H. T., El-Kabbani, O., Tajima, K., Iinuma, M., and Hara, A. (2011). Selective inhibition of the tumor marker aldoketo reductase family member 1B10 by oleanolic acid. J. Nat. Prod. 74, 1201-1206.
87. Tang, X. H., and Gudas, L. J. (2011). Retinoids, retinoic acid receptors, and cancer. Annu. Rev. Pathol. 6, 345-364.
88. Teramoto,R.,Minagawa,H.,Honda,M., Miyazaki, K., Tabuse, Y., Kamijo, K., Ueda, T., and Kaneko, S. (2008). Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim. Biophys. Acta 1784, 764-772.
89. Tirrò, E., Consoli, M. L., Massimino, M., Manzella, L., Frasca, F., Sciacca, L., Vicari, L., Stassi, G., Messina, L., Messina, A., and Vigneri, P. (2006). Altered expression of c- IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res. 66, 4263-4272.
90. Tomlinson, D., Knowles, M., and Speirs, V. (2012). Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int. J. Cancer.doi: 10.1002/ijc.26304. [Epub ahead of print].
91. Ueda, M., Hung, Y. C., Chen, J. T., Chiou, S. H., Huang, H. H., Lin, T. Y., Terai, Y., and Chow, K. C. (2006). Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. Gynecol. Oncol. 102, 173-181.
92. Vaziri, S. A., Grabowski, D. R., Tabata, M.,Holmes,K.A.,Sterk,J.,Takigawa, N., Bukowski, R. M., Ganapathi, M. K., and Ganapathi, R. (2003). c- IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apop- tosis. Anticancer Res. 23, 3657-3661.
93. Veitch, Z. W., Guo, B., Hembruff, S. L., Bewick, A. J., Heibein, A. D., Eng, J., Cull, S., Maclean, D. A., and Parissenti, A. M. (2009). Induction of 1C aldoketo reductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet. Genomics 19, 477-488.
94. Wang, C., Yan, R., Luo, D., Watabe, K., Liao, D. F., and Cao, D. (2009). Aldoketo reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J. Biol. Chem. 284, 26742-26748.
95. Wang, H. W., Lin, C. P., Chiu, J. H., Chow, K. C., Kuo, K. T., Lin, C. S., and Wang, L. S. (2007). Rever- sal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int. J. Cancer 120, 2019-2027.
96. Wang, R., Wang, G., Ricard, M. J., Ferris, B.,Strulovici-Barel,Y.,Salit,J.,Hackett, N. R., Gudas, L. J., and Crystal, R. G. (2010). Smoking-induced upregulation of AKR1B10 expression in the airway epithelium of healthy individuals. Chest 138, 1402-1410.
97. Wang, X. J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., Wong,P. K.,and Zhang,D. D. (2008). Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29, 1235-1243.
98. Woenckhaus, M., Klein-Hitpass, L., Grepmeier, U., Merk, J., Pfeifer, M., Wild, P., Bettstetter, M., Wuensch, P., Blaszyk, H., Hartmann, A., Hofstaedter, F., and Dietmaier,W. (2006). Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. J. Pathol. 210, 192-204.
99. Yabe-Nishimura, C. (1998). Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. 50, 21-33.
100. Yan, R., Zu, X., Ma, J., Liu, Z., Adeyanju, M., and Cao, D. (2007). Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int. J. Cancer 121, 2301-2306.
101. Yang, Y. L., and Li, X. M. (2000). The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res. 10, 169-177.
102. Yoshitake, H., Takahashi, M., Ishikawa, H., Nojima, M., Iwanari, H., Watan- abe, A., Aburatani, H., Yoshida, K., Ishi, K., Takamori, K., Ogawa, H., Hamakubo, T., Kodama, T., and Araki, Y. (2007). Aldo-keto reduc- tase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int. J. Gynecol. Cancer 17, 1300-1306.
103. Zhang, L., Lee, J. J., Tang, H., Fan, Y. H., Xiao, L., Ren, H., Kurie, J., Morice, R. C., Hong, W. K., and Mao, L. (2008). Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. Cancer Prev. Res. (Phila.) 1, 112-118.
104. Zhao, H. T., Soda, M., Endo, S., Hara, A., and El-Kabbani, O. (2010). Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like pro- tein (AKR1B10) discovered from molecular docking and database screening. Eur. J. Med. Chem. 45, 4354-4357.
105. Zhong, L., Liu, Z., Yan, R., Johnson, S., Zhao, Y., Fang, X., and Cao, D. (2009). Aldo-keto reduc- tase family 1 B10 protein detoxi- fies dietary and lipid-derived α,β- unsaturated carbonyls at physiolog- ical levels. Biochem. Biophys. Res. Commun. 387, 245-250.
106. Zhong, L., Shen, H., Huang, C., Jing, H., and Cao, D. (2011). AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol. Appl. Pharmacol. 255, 40-47.
107. Zu, X., Yan, R., Ma, J., Liao, D., and Cao, D. (2009). AKR1B10: a poten- tial target for cancer therapy. Biosci. Hypotheses 2, 31-33.